RxDoctor Payments Data

Daniel Katz, DO

Family Medicine · Olympia, WANPI 1316087042

Payments from drug & device makers

$3,330in general payments, 2019–2025

Across 41 payments — averaging $81.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$962
  • Phathom Pharmaceuticals, Inc.$219
  • Novo Nordisk$208
  • Lilly USA, LLC$192
  • Abbott$184
  • plus $565 from 7 others

What the payments were for

  • Food & beverage$3,330100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,330 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$90,949
Medicare patients
263
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide105$115,567
JardianceEmpagliflozin54$68,388
OzempicSemaglutide12$16,208
EliquisApixaban14$14,701
XareltoRivaroxaban16$13,868
Repatha SureclickEvolocumab12$6,770
Spiriva RespimatTiotropium Bromide11$5,451
Atorvastatin Calcium371$4,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,805
Rosuvastatin Calcium198$3,299
Ezetimibe92$3,170
Gabapentin103$2,474
Levothyroxine Sodium259$2,145
Wixela InhubFluticasone Propion/Salmeterol16$1,710
Escitalopram Oxalate108$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$192$115,567105 claims
Boehringer IngelheimJardiance, Spiriva Respimat$962$73,84065 claims
Novo NordiskOzempic$208$16,20812 claims
PfizerEliquis$54$14,70114 claims
Johnson & JohnsonXarelto$95$13,86816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →